We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAFV600E-MUTANT, MSI-H/DMMR METASTATIC COL
Ongoing 2022
Cancer
AMGEN 20190172
Colorectal cancer
Ongoing 2022
Cancer
AMGEN 20190135
Basket – Solid Tumours
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation